Skip to main content

Table 1 Summary table of the meta-analysis

From: Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis

A) ER         
  Country Study design Disease N Age (range) Survival analysis Hazard ratios Follow-up, months
Athanassiadou 1999 [39] Greece R EC 80 62.7 (48–82) OS SC 140
Backe 1997 [54] German R EC 124 68 (30–94) OS Reported 57.6 (0.24–180)
Borazjani 1989 [40] USA R EC 44 66 (36–86) OS SC 120
Chambers 1988-1 [51] USA R EC 168 OS DE 24 (1–118.8)
Covens 2011 [45] USA P EC 67 OS, PFS SC 36
Creasman 1985 [13] USA R EC 168 63 (30–92) DFS DE 25 (1–74)
Engelsen 2008 [34] Norway R EC 230 OS SC 192
Felix 2012 [28] USA R EC 199 OS, RFS SC 42 (0.8–144)
Fukuda 1998 [14] Japan R EEC 92 60.3 (31–86) DFS, OS SC, reported 61.2 (0–174)
Gates 2006 [52] USA R EC 108 64.2 (27–95) OS DE 60
Gonzalez-Rodilla 2013 [20] Spain R EC 126 65.9 (43–88) OS Report 70
Gul 2010 [31] Turkey R EC 49 58.3 (30–81) OS DE 24
Huvila 2013 [61] Finland R EEC 182 67 (35–93) DFS Reported 62.8 (4.2–84.4)
Ito 2005 [57] Japan R EEC 103 57 OS Reported 60 (2–148)
Jongen 2009 [17] Netherlands R EEC 315 64.7 (32–89) DSS, RFS, OS SC 59.6 (0–258)
Kadar 1993 [16] USA R EC 137 OS DE 60
Kamat 2009 [32] USA R EEC 139 63 (27–91) DSS Reported 24.9
Kalogiannidis 2008 [35] Greece R EC 77 62.5 (35–80) OS, CSS, DFS DE 60 (9–120)
Kauppila 1986 [42] Finland R EC 153 DFS, OS SC 42 (12–96)
Krakstad 2012-primary [27] Norway P EC 182 DSS SC 60
Krakstad 2012-prospective [27] Norway P EC 474 DSS SC 60
Lenhard 2013 [59] German P EC 292 65.1 (35.6–88) OS Reported 13.8 (13.1–14.5)
Liao 1986 [43] USA R EC 75 OS SC 50
Lindahl 1992 [50] Sweden R EC 298 63 (36–87) OS DE 60
Martin 1983 [44] Australia P EC 87 (48–85) OS SC (8–68)
Merritt 2010 [55] USA R EEC 85 63.4 (39–91) DSS Reported 72
Mhawech-Fauceglia 2013 [48] USA R EC 316 OS DE 60
Mylonas 2010 [30] Germany R EEC 214 65.1 (35–88) PFS, CSS, OS SC 96.3 (0.03–176.8)
Palmer 1988 [41] Australia R EC 351 64.5 (31–89) OS SC 100
Pertschuk 1996 [47] Caucasian, Hispanic, Oriental R EC 78 65.5 (38–89) OS SC 37.5 (13–161)
Pradhan 2012 [26] Norwegian P UPSC 52 72 (56–89) OS, PFS DE 60
Saito 2006 [56] Japan R EEC 103 57 DFS, OS Reported 60 (2–148)
Rahman 2013 [18] Japan R EEC 111 60 (26–85) PFS, OS Reported 52 (5–139)
Salvesen 1998 [58] Norway P EC 97 65 (37–92) OS DE 108 (60–180)
Shabani 2007 [36] Germany R EC 293 64.8 (35.5–88) PFS, CSS, OS SC 89.6 (3.2–135.5)
Sho 2014 [60] Japan R UPSC 33 69.6 (55–82) CSS Reported 29 (2–174)
Singh 2007 [37] USA P EC 48 OS Reported 19
Sivridis 2001 [38] Greece R EC 164 OS SC 55 (19–167)
Song 2012 [29] Korea R EC 137 53.7 (30–82) OS Reported 60
Sun 2013 [46] China P EC 73 58 (30–78) DFS SC 43.4 (16–91)
Voss 2011 [22] England P EC 156 68.2 (37–89) DSS, RFS Reported 48.1 (0.1–141.5)
Wik 2013-R [49] Norway R EC 266 DSS SC 300
Wik 2013-P [49] Norway P EC 153 DSS SC 300
Zannoni 2013 [25] Italy P EEA 121 59 (35–88) DFS, OS Reported 38 (14–91)
Zhang 2013 [53] China R EC 239 54 (26–82) DFS, OS DE 67 (12–183)
Zou 2012 [21] China R EEC 60 51.3 (30–72) OS Reported 45.5 (3–69.5)
B) PR         
  Country Study design Disease N Age (range) Survival analysis Hazard ratios Follow-up, months
Athanassiadou 1999 [39] Greece R EC 80 62.7 (48–82) OS SC 140
Backe 1997 [54] German R EC 197 68 (30–94) OS Reported 57.6 (0.2–180)
Borazjani 1989 [40] USA R EC 44 66 (36–86) OS SC 120
Chambers 1988-1 [51] USA R EC 168 67 (49–90) OS DE 24 (1–118.8)
Creasman 1985 [13] USA R EC 105 63 (30–92) DFS DE 25 (1–74)
Ehrlich 1988 [65] USA R EC 174 56 (25–89) OS SC 27 (1–152)
Engelsen 2008 [34] Norway R EC 230 OS Reported 192
Fukuda 1998 [14] Japan R EEC 92 60.3 (31–86) DFS SC 61.2 (0–174)
Gates 2006 [52] USA R EC 108 64.2 (27–95) OS Report 60
Gonzalez-Rodilla 2013 [20] Spain R EC 126 65.9 (43–88) OS Reported 70
Gul 2010 [31] Turkey R EC 49 58.3 (30–81) OS DE 24
Huvila 2013 [61] Finland R EEC 182 67 (35–93) DFS Reported 62.8 (4.2–84.4)
Ito 2005 [57] Japan R EEC 103 57 DFS, OS Reported 60 (2–148)
Jongen 2009 [17] Netherlands R EEC 300 64.7 (32.0–89.0) DSS, RFS, OS SC, reported 59.6 (0–258)
Kadar 1993 [16] USA R EC 137 OS DE 60
Kalogiannidis 2008 [35] Greece R EC 77 62.5 (35–80) OS, CSS, DFS DE 60 (9–120)
Kamat 2009 [32] USA R EEC 139 63 (27–91) DSS report 24.9
Kauppila 1986 [42] Finland R EC 153 DFS, OS SC 42 (12–96)
Liao 1986 [43] USA R EC 86   OS SC 50
Lenhard 2013 [59] German P EC 292 65.1 (35.6–88.1) OS Reported 13.8 (13.1–14.5)
Lindahl 1992 [50] Sweden R EC 272 63 (36–87) OS DE 60
Merritt 2010 [55] USA R EEC 85 63.4 (39–91) DSS Reported 72
Palmer 1988 [41] Australia R EC 351 64.5 (31–89) OS SC 100
Pradhan 2012 [26] Norwegian P SAC 50 72 (56–89) OS, PFS DE 60
Rahman 2013 [18] Japanese R EEC 110 60 (26–85) PFS, OS Reported 52 (5–139)
Sakaguchi 2004 [62] Japan R EC 120 32–74 OS SC 60
Saito 2006 [56] Japan P EEC 103 57 DFS, OS Reported 60 (2–148)
Salvesen 1998 [58] Norway P EC 96 65 (37–92) OS Reported 108 (60–180)
Shabani 2007 [36] Germany R EC 293 64.8 (35.5–87.9) PFS, CSS, OS SC 89.6 (3.2–135.5)
Singh 2007 [37] USA P EC 49   OS Reported 19
Sivridis 2001 [38] Greece R EC 164 OS SC 55 (19–167)
Song 2012 [29] Korea R EC 137 53.7 (30–82) OS Reported 60
Steiner 2003 [63] Germany R EC 115 65 (38–81) OS, RFS SC 72 (36–156)
Sutton 1989 [64] USA R EC 139 61 (31–89) DFS SC, DE 28.9 (1–128)
Voss 2011 [22] England P EC 156 68.2 (37–89) DSS, RFS Reported 48.1 (0.1–141.5)
Zannoni 2013 [25] Italy P EEC 121 59 (35–88) DFS, OS Reported 38 (14–91)
Zhang 2013 [53] China R EC 239 54 (26–82) DFS, OS, RFS SC 67 (12–183)
Zou 2012 [21] China R EEC 60 51.3 (30–72) OS Reported 45.5 (3–69.5)
C) HER2         
  Country Study design Disease N Age (range) Survival analysis Hazard ratios Follow-up, months
Backe 1997 [54] German R EC 222 68 (30–94) OS, RFS SC 57.6 (0.24–180)
Cianciulli 2003 [76] Italy R EC 73   OS SC 72
Coronado 2001 [72] Spain R EC 114 65 (37–85) PFS SC 6 (14–107)
Gates 2006 [52] USA R EC 99 64.2 (27–95) OS report 60
Gonzalez-Rodilla 2013 [20] Spain R EC 126 65.9 (43–88) OS report 70
Jongen 2009-2 [33] Netherlands P EEC 315 64.7 (32–89) OS, RFS Reported 59.6 (0–258)
Kohlberger 1996 [73] Australia R EC 100 64 (36–85) OS SC 140
Konecny 2009 [68] USA R EC 273 65 (38–90) OS SC EEA83 (0.3–270) USPC20 (0.1–162), CCC38 (0.2–180)
Mori 2010 [67] Japan R EEC 63 57.5 (32–78) RFS, OS SC 61.9 (7–133)
Odicino 2008 [69] Italy R USPC 10 positive: 79–84; negative: 57–76 OS DE 19.7 (1–87)
Peiro 2004 [76] German R EC 10 60 (29–91) OS SC, reported 53
Saffari 1995 [74] Hispanic R EC 75 60 (29–87) OS SC 144
Santin 2005-1 [70] USA R USPC 27 66 (62–75) DSS, OS SC, reported 33 (10–48)
Santin 2005-2 [71] USA R USPC 30 67.5 (63–75) OS SC 42 (10–51)
Togami 2012 [66] Japan R UPSC 71 63.6 (47–81) RFS, OS Reported 49.7 (4–125)
Voss 2011 [22] England P EC 156 68.2 (37–89) DSS, RFS Reported 48.12 (0.12–141.48)
  1. Study design is described as prospective (P) or retrospective (R)
  2. EC endometrial cancer, EEC endometrioid endometrial cancer, UPSC uterine papillary serous carcinoma, OS overall survival, CSS cancer-specific survival, DSS disease-specific survival, PFS progression-free survival, RFS relapse-free survival, DFS disease-free survival, DE data-extrapolated, SC survival curve
  3. not reported
  4. [ ]Reference number